112 related articles for article (PubMed ID: 27734427)
1. EPCA2.22: A Silver Lining for Early Diagnosis of Prostate Cancer.
Pourmand G; Safavi M; Ahmadi A; Houdeh E; Noori M; Mashhadi R; Alizadeh F; Salimi E; Heydari F; Mehrsai A; Pourmand N
Urol J; 2016 Oct; 13(5):2845-2848. PubMed ID: 27734427
[TBL] [Abstract][Full Text] [Related]
2. Association of serum EPCA-2 level with prostate cancer in Chinese Han population.
Wang L; Ma L; Wang X; Li B; Guo S; Qiao Q
Int J Clin Exp Pathol; 2015; 8(8):9397-403. PubMed ID: 26464694
[TBL] [Abstract][Full Text] [Related]
3. Analysis of a serum test for prostate cancer that detects a second epitope of EPCA-2.
Leman ES; Magheli A; Cannon GW; Mangold L; Partin AW; Getzenberg RH
Prostate; 2009 Aug; 69(11):1188-94. PubMed ID: 19418497
[TBL] [Abstract][Full Text] [Related]
4. Serum early prostate cancer antigen (EPCA) as a significant predictor of incidental prostate cancer in patients undergoing transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Zeng G; Zhong W
Prostate; 2010 Dec; 70(16):1788-98. PubMed ID: 20583137
[TBL] [Abstract][Full Text] [Related]
5. EPCA-2: a highly specific serum marker for prostate cancer.
Leman ES; Cannon GW; Trock BJ; Sokoll LJ; Chan DW; Mangold L; Partin AW; Getzenberg RH
Urology; 2007 Apr; 69(4):714-20. PubMed ID: 17445657
[TBL] [Abstract][Full Text] [Related]
6. Clinical Value of Magnetic Resonance Imaging Combined With Serum Prostate-specific Antigen, Epithelial Cadherin and Early Prostate Cancer Antigen 2 In Diagnosis of Prostate Cancer.
Li K; Luan Q; Zheng J; Li R; Li L; Sun Y; Liu D
Anticancer Res; 2023 Jan; 43(1):441-447. PubMed ID: 36585192
[TBL] [Abstract][Full Text] [Related]
7. Serum early prostate cancer antigen (EPCA) level and its association with disease progression in prostate cancer in a Chinese population.
Zhao Z; Ma W; Zeng G; Qi D; Ou L; Liang Y
PLoS One; 2011 May; 6(5):e19284. PubMed ID: 21559289
[TBL] [Abstract][Full Text] [Related]
8. Increased serum level of early prostate cancer antigen is associated with subsequent cancer risk in men with high-grade prostatic intraepithelial neoplasia.
Zhao Z; Zeng G
Endocr Relat Cancer; 2010 Jun; 17(2):505-12. PubMed ID: 20308359
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen complexed to alpha(1)-antichymotrypsin in the early detection of prostate cancer.
Martínez M; España F; Royo M; Vera CD; Estellés A; Jiménez-Cruz JF; Medina P; Aznar J
Eur Urol; 2000 Jul; 38(1):85-90. PubMed ID: 10859447
[TBL] [Abstract][Full Text] [Related]
10. Preoperative serum levels of early prostate cancer antigen (EPCA) predict prostate cancer progression in patients undergoing radical prostatectomy.
Zhao Z; Ma W; Zeng G; Qi D; Ou L; Liang Y
Prostate; 2012 Feb; 72(3):270-9. PubMed ID: 21630293
[TBL] [Abstract][Full Text] [Related]
11. Detection of prostate cancer with a blood-based assay for early prostate cancer antigen.
Paul B; Dhir R; Landsittel D; Hitchens MR; Getzenberg RH
Cancer Res; 2005 May; 65(10):4097-100. PubMed ID: 15899799
[TBL] [Abstract][Full Text] [Related]
12. Free and total PSA in the diagnosis of prostate cancer.
Filella X; Alcover J; Molina R; Rodríguez A; Carretero P; Ballesta AM
Tumour Biol; 1997; 18(6):332-40. PubMed ID: 9372866
[TBL] [Abstract][Full Text] [Related]
13. Detection of prostate cancer and changes in prostate-specific antigen (PSA) six months after surgery for benign prostatic hyperplasia in patients with elevated PSA.
Ozden C; Inal G; Adsan O; Yazici S; Ozturk B; Cetinkaya M
Urol Int; 2003; 71(2):150-3. PubMed ID: 12890951
[TBL] [Abstract][Full Text] [Related]
14. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
[TBL] [Abstract][Full Text] [Related]
15. [Serum and urine prostate-specific antigen ratio: its value in the distinction between prostate cancer and adenoma when serum prostate-specific antigen level is between 4 and 10 ng/ml].
Irani J; Millet C; Levillain P; Doré B; Bégon F; Aubert J
Chirurgie; 1997; 122(8-9):478-82. PubMed ID: 9616891
[TBL] [Abstract][Full Text] [Related]
16. Prostate specific antigen density of the transition zone for early detection of prostate cancer.
Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M
J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia.
Bogdanowicz JF; Bentvelsen FM; Oosterom R; Schroeder FH
Scand J Urol Nephrol Suppl; 1991; 138():97-103. PubMed ID: 1723815
[TBL] [Abstract][Full Text] [Related]
18. Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology.
Roehrborn CG; Gregory A; McConnell JD; Sagalowsky AI; Wians FH
Urology; 1996 Dec; 48(6A Suppl):23-32. PubMed ID: 8973696
[TBL] [Abstract][Full Text] [Related]
19. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
[TBL] [Abstract][Full Text] [Related]
20. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer.
Benson MC; Whang IS; Pantuck A; Ring K; Kaplan SA; Olsson CA; Cooner WH
J Urol; 1992 Mar; 147(3 Pt 2):815-6. PubMed ID: 1371554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
